Skip to main navigation Skip to search Skip to main content

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

  • Artur Jurczyszyn
  • , Magdalena Olszewska-Szopa
  • , Vania Hungria
  • , Edvan Crusoe
  • , Tomas Pika
  • , Michel Delforge
  • , Xavier Leleu
  • , Leo Rasche
  • , Ajay K. Nooka
  • , Agnieszka Druzd-Sitek
  • , Jan Walewski
  • , Julio Davila
  • , Jo Caers
  • , Vladimir Maisnar
  • , Morie Gertz
  • , Massimo Gentile
  • , Dorotea Fantl
  • , Giuseppe Mele
  • , David H. Vesole
  • , Andrew J. Yee
  • Chaim Shustik, Suzanne Lentzsch, Sonja Zweegman, Alessandro Gozzetti, Aleksander B. Skotnicki, Jorge J. Castillo
  • Jagiellonian University Medical College
  • Wrocław Medical University
  • Faculdade de Ciências Médicas Santa Casa de São Paulo
  • University Hospital Olomouc
  • KU Leuven
  • CHU de Poitiers
  • University of Würzburg
  • Emory University
  • Maria Sklodowska-Curie Institute of Oncology
  • Hospital Clínico Universitario de Salamanca
  • University of Liege
  • Department of Medicine – Haematology
  • Mayo Clinic Rochester, MN
  • Hematology Unit
  • Hospital Italiano de Buenos Aires
  • Ospedale A. Perrino
  • Harvard University
  • McGill University
  • Columbia University
  • VU University Medical Center
  • Azienda Ospedaliera Universitaria Senese

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Abstract: Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.

Original languageEnglish
Pages (from-to)2071-2076
Number of pages6
JournalLeukemia and Lymphoma
Volume57
Issue number9
DOIs
StatePublished - 1 Sep 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cutaneous
  • diagnosis
  • myeloma
  • skin
  • treatment

Fingerprint

Dive into the research topics of 'Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients'. Together they form a unique fingerprint.

Cite this